Agreement includes remote and on-site chemistry support.
NovAlix entered into a multiyear research services agreement to support the drug discovery efforts of Janssen-Cilag. The agreement includes remote and on-site chemistry support by NovAliX scientists. Janssen-Cilag focuses on five therapeutic areas: cardiovascular and metabolic diseases, immunology, infectious diseases and vaccines, neuroscience, and oncology.
NovAlix’ technologies include SPR technology, X-ray protein crystallography, and supramolecular mass spectrometry. Its services include organic synthetic chemistry services and biophysical capabilities focused on small molecule drug discovery.
NovAlix expanded its research services capabilities last year through two acquisitions. The company picked up Graffinity Pharmaceuticals for its small molecule library and patented SPR-imaging technology last November. In January 2010, NovAlix bought NMRTec for its NMR solutions capabilities.